LAUSR.org creates dashboard-style pages of related content for over 1.5 million academic articles. Sign Up to like articles & get recommendations!

Successful treatment of secukinumab‐resistant palmoplantar pustulosis by Dupilumab: A case report

Palmoplantar pustulosis (PPP) is a chronic inflammatory skin disease characterized by erythema, scales, and sterile pustules on the palms and soles. 1 Recent studies have focused on the importance of… Click to show full abstract

Palmoplantar pustulosis (PPP) is a chronic inflammatory skin disease characterized by erythema, scales, and sterile pustules on the palms and soles. 1 Recent studies have focused on the importance of inter-leukin (IL)-17 and IL-36 pathways in the pathogenesis of PPP 1 . Dupilumab, an anti-IL-4-receptor- α monoclonal antibody, is currently used as treatment and often administered to patients with atopic dermatitis. 2 Herein, we describe a case of secukinumab-resistant PPP that was successfully treated with dupilumab.

Keywords: secukinumab resistant; treatment; dupilumab; palmoplantar pustulosis

Journal Title: Dermatologic Therapy
Year Published: 2022

Link to full text (if available)


Share on Social Media:                               Sign Up to like & get
recommendations!

Related content

More Information              News              Social Media              Video              Recommended



                Click one of the above tabs to view related content.